Roth Capital analyst David Solomon initiated Sensus Healthcare with a Buy rating and $12.50 price target, as he sees the company being able to sustain its revenue growth as it capitalizes on the resurgence of superficial radiation therapy for nonmelanoma skin cancer and intra-operative radiation therapy for solid tumors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.